Protagonist Therapeutics Form 4: CEO gifts 620 PTGX shares

Rhea-AI Filing Summary

Dinesh V. Patel, Ph.D., President and CEO and director of Protagonist Therapeutics, Inc. (PTGX), reported a change in beneficial ownership on Form 4. The filing discloses a transaction dated 09/16/2025 in which Dr. Patel made a bona fide gift of 620 shares of the issuer's common stock to his son at a reported price of $0 (coded G). After the reported transaction, Dr. Patel beneficially owned 519,983 shares, held directly. The Form 4 was signed on 09/18/2025 by Matthew Gosling as attorney-in-fact for Dr. Patel.

Positive

• Timely and specific disclosure of the insider transaction including date, amount, and post-transaction holdings
• Transaction clearly identified as a bona fide gift (coded G) to a family member, with price reported as $0

Negative

• Reduction in direct holdings by 620 shares (transaction recorded as a disposal) is noted in the filing

Insights

Securities/Insider Transactions Analyst

TL;DR: Small, non-sale transfer: an insider gift of 620 shares reduces direct holdings but involves no cash proceeds.

The Form 4 documents a bona fide gift by the reporting person rather than a market sale, reflected by transaction code G and price $0. The filing states the reporting person remains a significant insider as President, CEO and director and continues to hold 519,983 shares directly. From a transactional perspective this is a routine insider transfer; the filing provides clear disclosure of the date, amount transferred, resulting beneficial ownership, and the signature by an attorney-in-fact.

Corporate Governance Expert

TL;DR: Governance disclosure appears complete and timely for a personal gift by a named executive.

The report identifies the reporting person’s roles and the nature of the transfer as a gift to a family member, which aligns with required disclosure practices for Section 16 insiders. The Form 4 includes the transaction date, transaction code, number of shares transferred, the post-transaction beneficial ownership figure, and an executed signature page. No additional corporate actions, sales, or changes in officer/director status are disclosed in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

PATEL DINESH V PH D

(Last) (First) (Middle)

C/O PROTAGONIST THERAPEUTICS, INC.

7707 GATEWAY BLVD., SUITE 140

(Street)

NEWARK CA 94560-1160

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Protagonist Therapeutics, Inc [ PTGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/16/2025		G(1)		620	D	$0	519,983	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction involves a bona fide gift of securities from the Reporting Person to his son.

	/s/ Matthew Gosling, Attorney-in-Fact for Dinesh V. Patel, Ph.D.	09/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What change did PTGX insider Dinesh V. Patel report on Form 4?

The Form 4 reports a bona fide gift of 620 shares of Protagonist Therapeutics common stock on 09/16/2025.

How many PTGX shares does Dinesh V. Patel beneficially own after the reported transaction?

After the reported gift, Dr. Patel beneficially owned 519,983 shares of PTGX, held directly.

What was the reported price and transaction code for the PTGX transfer?

The transaction is coded G (gift) with a reported price of $0.

When was the Form 4 for PTGX signed and who signed it?

The Form 4 was signed on 09/18/2025 by Matthew Gosling as attorney-in-fact for Dinesh V. Patel.

What positions does the reporting person hold at Protagonist Therapeutics?

The filing lists the reporting person as a Director and as an Officer with the title President and CEO.